473 related articles for article (PubMed ID: 18722004)
1. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of annual screening strategies for endometrial cancer.
Havrilesky LJ; Maxwell GL; Myers ER
Am J Obstet Gynecol; 2009 Jun; 200(6):640.e1-8. PubMed ID: 19380121
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
5. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic screening for gastric cancer.
Dan YY; So JB; Yeoh KG
Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of a test to detect metastases for endometrial cancer.
Havrilesky LJ; Maxwell GL; Chan JK; Myers ER
Gynecol Oncol; 2009 Mar; 112(3):526-30. PubMed ID: 19100608
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
Kwon JS; Lu KH
Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
[TBL] [Abstract][Full Text] [Related]
13. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
Plunkett BA; Grobman WA
Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.
Xie F; Luo N; Blackhouse G; Goeree R; Lee HP
Int J Technol Assess Health Care; 2008; 24(1):87-95. PubMed ID: 18218173
[TBL] [Abstract][Full Text] [Related]
15. Screening for renal cancer in recipients of kidney transplants.
Wong G; Howard K; Webster AC; Chapman JR; Craig JC
Nephrol Dial Transplant; 2011 May; 26(5):1729-39. PubMed ID: 20961889
[TBL] [Abstract][Full Text] [Related]
16. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of anal cancer screening in HIV-positive women.
Lazenby GB; Unal ER; Andrews AL; Simpson K
J Low Genit Tract Dis; 2012 Jul; 16(3):275-80. PubMed ID: 22227844
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
